AstraZeneca signs potential $240M R&D deal with Alchemia

04/24/2013 | Genetic Engineering & Biotechnology News

Alchemia and AstraZeneca agreed to collaborate in the discovery and potential development of novel small molecules against multiple targets using the former's Diversity Scanning Array and Versatile Assembly on Stable Templates chemistry technology. AstraZeneca will pay Alchemia an undisclosed upfront fee, research funding, and as much as $240 million in milestone fees plus royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX